Nitrous Oxide For Endoscopic Ablation of Refractory Barretts Esophagus (NO FEAR-BE)
Study of C2 CryoBalloon Focal Ablation System for Patients with Barrett's Esophagus
Sponsor: C2 Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAR9084
U.S. Govt. ID: NCT03554356
Contact: Dr. Julian Abrams: 212-305-1909 /
Additional Study Information: This research study will look at a newer treatment option for Barrett's Esophagus (BE) which uses nitrous Oxide to freeze unwanted tissue. The most commonly used treatment method is Radiofrequency Ablation (RFA) which uses heat to destroy the pre-cancerous tissue. Nitrous Oxide ablation using the C2 CryoBalloon Focal Ablation System, an FDA-cleared device, is another, newer way of treating Barrett's Esophagus. To evaluate the newer treatment, we are enrolling patients who are not responding as well as expected to RFA in a research study. Patients with at least 2 or more previous RFA treatments who still have BE may be eligible. Participants will be in the study for up to 2 years. All study visits and treatments received will be part of normal clinical care. The study team will ask you to complete surveys and answer questions about your health, and collect information about your health from your medical record. If you are a patient who still has Barrett's Esophagus after receiving 2 or more ablation treatments, or you are a physician with a patient who might be eligible, please reach out to us.
Julian Abrams, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have a history of esophageal cancer? Yes No
Are you willing to undergo an experimental treatment for your type of cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Dr. Julian Abrams